We thank our Data and Safety Monitoring Committee, our TSC and Trial Management Group members, and our patient and public involvement and engagement representatives who reviewed the trial protocol and participated in our TSC and Monitoring Committees
April 2026: As of April 1, 2026, there are 73 pending lawsuits in MDL 3163 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation , which involves claims against Novo Nordisks Wegovy
Current coverage includes major population centers across California, Florida, New York, Texas, and many others
In conclusion, Sema treatment reduced glycolysis and promoted its substrates into the TCA cycle to increase myocardial energy supply and reduce the lipid accumulation of TAC-induced pathological myocardial remodeling
Triple-receptor agonists or triagonists in development target GLP-1, GIP, and glucagon receptors